[Correspondence] Nafithromycin in CABP: promise and precaution

We read with interest the recent phase III trial comparing nafithromycin with moxifloxacin for community-acquired bacterial pneumonia (CABP).1 The investigators are to be commended for conducting a large, multicentre, double-blind study of a novel oral macrolide. The evaluation of a short-course regimen against an established comparator adds important data to the field and highlights the potential role of new macrolides in CABP management.